Selection and expansion of natural killer cells for NK cell-based immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Authors
Keywords
Hematopoietic stem cell transplantation, Immunotherapy, Killer cell immunoglobulin-like receptor, Natural killer cells
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 4, Pages 477-484
Publisher
Springer Nature
Online
2016-01-25
DOI
10.1007/s00262-016-1792-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients
- (2015) Martino Monteverde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Challenges of cancer therapy with natural killer cells
- (2015) Hans Klingemann CYTOTHERAPY
- KIR alloreactivity based on the receptor–ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study
- (2015) Silvia Park et al. HUMAN IMMUNOLOGY
- Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer
- (2015) Naoyuki Sakamoto et al. Journal of Translational Medicine
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
- (2015) David L. Hermanson et al. Frontiers in Immunology
- Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells
- (2014) Jeffrey W. Leong et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL
- (2014) L. Oevermann et al. BLOOD
- Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy
- (2014) Denise Skrombolas et al. Expert Review of Clinical Immunology
- Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide
- (2014) I. S. Nijhof et al. HAEMATOLOGICA
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Donor Activating KIR2DS1 in Leukemia
- (2014) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frozen Cord Blood Hematopoietic Stem Cells Differentiate into Higher Numbers of Functional Natural Killer Cells In Vitro than Mobilized Hematopoietic Stem Cells or Freshly Isolated Cord Blood Hematopoietic Stem Cells
- (2014) Martha Luevano et al. PLoS One
- Clinical utility of natural killer cells in cancer therapy and transplantation
- (2014) David A. Knorr et al. SEMINARS IN IMMUNOLOGY
- CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells
- (2014) J. Du et al. Cancer Immunology Research
- Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors
- (2014) Lorenzo Moretta et al. Frontiers in Immunology
- Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies
- (2014) Salem Chouaib et al. Frontiers in Immunology
- Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?
- (2014) Renato Zambello et al. Frontiers in Immunology
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
- (2013) M. L. Green et al. BLOOD
- "Designed" grafts for HLA-haploidentical stem cell transplantation
- (2013) M. F. Martelli et al. BLOOD
- Ex Vivo Expansion of Highly Cytotoxic Human NK Cells by Cocultivation with Irradiated Tumor Cells for Adoptive Immunotherapy
- (2013) S. A. Lim et al. CANCER RESEARCH
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation
- (2013) Rafijul Bari et al. JOURNAL OF CLINICAL ONCOLOGY
- NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand
- (2013) G. Pittari et al. JOURNAL OF IMMUNOLOGY
- Irradiated and Activated Autologous PBMCs Induce Expansion of Highly Cytotoxic Human NK Cells In Vitro
- (2013) Yong-Oon Ahn et al. JOURNAL OF IMMUNOTHERAPY
- GMP-Compliant, Large-Scale Expanded Allogeneic Natural Killer Cells Have Potent Cytolytic Activity against Cancer Cells In Vitro and In Vivo
- (2013) Okjae Lim et al. PLoS One
- Engineered Human Embryonic Stem Cell-Derived Lymphocytes to Study In Vivo Trafficking and Immunotherapy
- (2013) David A. Knorr et al. STEM CELLS AND DEVELOPMENT
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells
- (2013) Franco Locatelli et al. Frontiers in Immunology
- Signatures of Human NK Cell Development and Terminal Differentiation
- (2013) Merlin Luetke-Eversloh et al. Frontiers in Immunology
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
- (2013) Ulrike Koehl et al. Frontiers in Oncology
- Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation
- (2012) X. Wang et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission
- (2012) Yeh-Ching Linn et al. CYTOTHERAPY
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Haploidentical Hematopoietic Stem Cell Transplantation With a Megadose T-Cell–Depleted Graft: Harnessing Natural and Adaptive Immunity
- (2012) Franco Aversa et al. SEMINARS IN ONCOLOGY
- Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I
- (2011) K. Schonberg et al. BLOOD
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
- (2011) B. Foley et al. BLOOD
- Ex vivo differentiation of natural killer cells from human umbilical cord blood CD34+progenitor cells
- (2011) Maria João Pinho et al. CELL COMMUNICATION AND ADHESION
- Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies
- (2011) Garnet Suck et al. EXPERIMENTAL HEMATOLOGY
- Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
- (2011) Kory L. Alderson et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
- (2011) Jan Spanholtz et al. PLoS One
- IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study
- (2011) Claudia Brehm et al. PLoS One
- Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation
- (2010) J. M. Venstrom et al. BLOOD
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients
- (2010) Uwe Siegler et al. CYTOTHERAPY
- High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
- (2010) Jan Spanholtz et al. PLoS One
- Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
- (2009) P. S. Woll et al. BLOOD
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells
- (2009) U. Langenkamp et al. HAEMATOLOGICA
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
- (2008) S. Cooley et al. BLOOD
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Generation of functional natural killer and dendritic cells in a human stromal-based serum-free culture system designed for cord blood expansion
- (2007) Ana M. Frias et al. EXPERIMENTAL HEMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now